Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: UQCRHL

Gene summary for UQCRHL

Gene summary.

Gene information	Species	Human
	Gene symbol	UQCRHL
	Gene ID	440567
	Gene name	ubiquinol-cytochrome c reductase hinge protein like
	Gene Alias	hCG25371
	Cytomap	1p36.21
	Gene Type	protein-coding
	GO ID	GO:0006091
	UniProtAcc	A0A096LP55

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
440567	UQCRHL	GSM6177620_NYU_UCEC1_lib1_lib1	Human	Endometrium	EEC	5.36e-15	5.88e-01	-0.1869
440567	UQCRHL	GSM6177620_NYU_UCEC1_lib2_lib2	Human	Endometrium	EEC	4.10e-09	5.00e-01	-0.1875
440567	UQCRHL	GSM6177620_NYU_UCEC1_lib3_lib3	Human	Endometrium	EEC	1.02e-12	5.14e-01	-0.1883
440567	UQCRHL	GSM6177622_NYU_UCEC3_lib1_lib1	Human	Endometrium	EEC	4.11e-06	3.10e-01	-0.1917
440567	UQCRHL	P1T-E	Human	Esophagus	ESCC	9.42e-08	3.65e-01	0.0875
440567	UQCRHL	P2T-E	Human	Esophagus	ESCC	3.94e-03	1.15e-01	0.1177
440567	UQCRHL	P4T-E	Human	Esophagus	ESCC	4.69e-05	2.38e-01	0.1323
440567	UQCRHL	P5T-E	Human	Esophagus	ESCC	1.09e-15	3.12e-01	0.1327
440567	UQCRHL	P8T-E	Human	Esophagus	ESCC	4.57e-02	1.16e-01	0.0889
440567	UQCRHL	P9T-E	Human	Esophagus	ESCC	7.61e-07	1.32e-01	0.1131
440567	UQCRHL	P10T-E	Human	Esophagus	ESCC	1.02e-09	1.40e-01	0.116
440567	UQCRHL	P11T-E	Human	Esophagus	ESCC	3.17e-05	2.06e-01	0.1426
440567	UQCRHL	P15T-E	Human	Esophagus	ESCC	1.89e-05	1.75e-01	0.1149
440567	UQCRHL	P20T-E	Human	Esophagus	ESCC	2.31e-04	1.92e-01	0.1124
440567	UQCRHL	P21T-E	Human	Esophagus	ESCC	5.90e-20	4.41e-01	0.1617
440567	UQCRHL	P22T-E	Human	Esophagus	ESCC	2.01e-02	1.11e-01	0.1236
440567	UQCRHL	P23T-E	Human	Esophagus	ESCC	1.73e-06	2.60e-01	0.108
440567	UQCRHL	P24T-E	Human	Esophagus	ESCC	2.71e-05	1.19e-01	0.1287
440567	UQCRHL	P26T-E	Human	Esophagus	ESCC	1.77e-06	1.50e-01	0.1276
440567	UQCRHL	P27T-E	Human	Esophagus	ESCC	1.11e-07	1.81e-01	0.1055

Page: 1 2 3 4

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0042773110	Esophagus	ESCC	ATP synthesis coupled electron transport	74/8552	95/18723	1.28e-10	3.77e-09	74
GO:0042775110	Esophagus	ESCC	mitochondrial ATP synthesis coupled electron transport	74/8552	95/18723	1.28e-10	3.77e-09	74
GO:0019646110	Esophagus	ESCC	aerobic electron transport chain	67/8552	87/18723	2.30e-09	5.14e-08	67
GO:0006122110	Esophagus	ESCC	mitochondrial electron transport, ubiquinol to cytochrome c	10/8552	11/18723	2.54e-03	1.08e-02	10
GO:000609112	Liver	Cirrhotic	generation of precursor metabolites and energy	238/4634	490/18723	6.85e-31	1.07e-27	238
GO:002290012	Liver	Cirrhotic	electron transport chain	111/4634	175/18723	1.94e-27	1.52e-24	111
GO:004603412	Liver	Cirrhotic	ATP metabolic process	144/4634	277/18723	1.04e-22	5.02e-20	144
GO:00427737	Liver	Cirrhotic	ATP synthesis coupled electron transport	69/4634	95/18723	1.12e-22	5.02e-20	69
GO:00427757	Liver	Cirrhotic	mitochondrial ATP synthesis coupled electron transport	69/4634	95/18723	1.12e-22	5.02e-20	69
GO:00090607	Liver	Cirrhotic	aerobic respiration	109/4634	189/18723	3.88e-22	1.62e-19	109
GO:00229047	Liver	Cirrhotic	respiratory electron transport chain	77/4634	114/18723	5.84e-22	2.29e-19	77
GO:00196467	Liver	Cirrhotic	aerobic electron transport chain	63/4634	87/18723	1.04e-20	3.43e-18	63
GO:00453337	Liver	Cirrhotic	cellular respiration	122/4634	230/18723	2.15e-20	6.43e-18	122
GO:001598012	Liver	Cirrhotic	energy derivation by oxidation of organic compounds	154/4634	318/18723	3.11e-20	8.87e-18	154
GO:00061197	Liver	Cirrhotic	oxidative phosphorylation	86/4634	141/18723	6.08e-20	1.66e-17	86
GO:00061227	Liver	Cirrhotic	mitochondrial electron transport, ubiquinol to cytochrome c	10/4634	11/18723	7.30e-06	1.13e-04	10
GO:000609122	Liver	HCC	generation of precursor metabolites and energy	340/7958	490/18723	4.04e-34	2.85e-31	340
GO:000906012	Liver	HCC	aerobic respiration	147/7958	189/18723	3.13e-23	6.61e-21	147
GO:004533312	Liver	HCC	cellular respiration	171/7958	230/18723	6.35e-23	1.26e-20	171
GO:004603422	Liver	HCC	ATP metabolic process	198/7958	277/18723	8.30e-23	1.55e-20	198

Page: 1 2 3 4

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa05014210	Esophagus	ESCC	Amyotrophic lateral sclerosis	266/4205	364/8465	1.31e-20	2.20e-18	1.13e-18	266
hsa05016210	Esophagus	ESCC	Huntington disease	226/4205	306/8465	1.38e-18	8.72e-17	4.46e-17	226
hsa05012211	Esophagus	ESCC	Parkinson disease	201/4205	266/8465	1.56e-18	8.72e-17	4.46e-17	201
hsa05208211	Esophagus	ESCC	Chemical carcinogenesis - reactive oxygen species	168/4205	223/8465	1.83e-15	6.81e-14	3.49e-14	168
hsa05022210	Esophagus	ESCC	Pathways of neurodegeneration - multiple diseases	318/4205	476/8465	6.10e-15	2.04e-13	1.05e-13	318
hsa05010210	Esophagus	ESCC	Alzheimer disease	263/4205	384/8465	1.80e-14	5.47e-13	2.80e-13	263
hsa04932210	Esophagus	ESCC	Non-alcoholic fatty liver disease	122/4205	155/8465	5.69e-14	1.59e-12	8.14e-13	122
hsa05020210	Esophagus	ESCC	Prion disease	193/4205	273/8465	6.42e-13	1.34e-11	6.89e-12	193
hsa00190210	Esophagus	ESCC	Oxidative phosphorylation	104/4205	134/8465	2.04e-11	2.98e-10	1.53e-10	104
hsa05415211	Esophagus	ESCC	Diabetic cardiomyopathy	146/4205	203/8465	5.81e-11	7.78e-10	3.99e-10	146
hsa04714211	Esophagus	ESCC	Thermogenesis	163/4205	232/8465	9.22e-11	1.14e-09	5.86e-10	163
hsa0501438	Esophagus	ESCC	Amyotrophic lateral sclerosis	266/4205	364/8465	1.31e-20	2.20e-18	1.13e-18	266
hsa0501638	Esophagus	ESCC	Huntington disease	226/4205	306/8465	1.38e-18	8.72e-17	4.46e-17	226
hsa05012310	Esophagus	ESCC	Parkinson disease	201/4205	266/8465	1.56e-18	8.72e-17	4.46e-17	201
hsa05208310	Esophagus	ESCC	Chemical carcinogenesis - reactive oxygen species	168/4205	223/8465	1.83e-15	6.81e-14	3.49e-14	168
hsa0502238	Esophagus	ESCC	Pathways of neurodegeneration - multiple diseases	318/4205	476/8465	6.10e-15	2.04e-13	1.05e-13	318
hsa0501038	Esophagus	ESCC	Alzheimer disease	263/4205	384/8465	1.80e-14	5.47e-13	2.80e-13	263
hsa0493238	Esophagus	ESCC	Non-alcoholic fatty liver disease	122/4205	155/8465	5.69e-14	1.59e-12	8.14e-13	122
hsa0502038	Esophagus	ESCC	Prion disease	193/4205	273/8465	6.42e-13	1.34e-11	6.89e-12	193
hsa0019038	Esophagus	ESCC	Oxidative phosphorylation	104/4205	134/8465	2.04e-11	2.98e-10	1.53e-10	104

Page: 1 2 3 4 5 6

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

UQCRHL

SNV

Missense_Mutation

novel

c.13N>A

p.Asp5Asn

p.D5N

A0A096LP55

protein_coding

tolerated(0.12)

benign(0.1)

TCGA-EK-A3GK-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

UQCRHL

SNV

Missense_Mutation

novel

c.176C>G

p.Ser59Cys

p.S59C

A0A096LP55

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-VS-A950-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unknown

UQCRHL

SNV

Missense_Mutation

rs774153442

c.244N>A

p.Val82Met

p.V82M

A0A096LP55

protein_coding

tolerated(0.06)

benign(0.037)

TCGA-A5-A0G9-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

UQCRHL

SNV

Missense_Mutation

novel

c.195G>T

p.Glu65Asp

p.E65D

A0A096LP55

protein_coding

deleterious(0)

probably_damaging(0.99)

TCGA-B5-A11E-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

UQCRHL

SNV

Missense_Mutation

rs780112142

c.179N>A

p.Arg60Gln

p.R60Q

A0A096LP55

protein_coding

tolerated(0.06)

benign(0.01)

TCGA-B5-A1MR-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

III/IV

Unknown

UQCRHL

SNV

Missense_Mutation

rs764654397

c.34G>A

p.Glu12Lys

p.E12K

A0A096LP55

protein_coding

tolerated(0.88)

benign(0.035)

TCGA-EO-A22X-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unspecific

Carboplatin

Complete Response

UQCRHL

SNV

Missense_Mutation

novel

c.86N>A

p.Pro29His

p.P29H

A0A096LP55

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-EO-A3KX-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

UQCRHL

insertion

Nonsense_Mutation

novel

c.31_32insAATAAGAAACAAATGGTACAT

p.Thr11delinsLysTerGluThrAsnGlyThrSer

p.T11delinsK*ETNGTS

A0A096LP55

protein_coding

TCGA-BS-A0UJ-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1